Clinical trial

Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer

NCT04379739

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2020-07-26

PhasePHASE2

Study timeline

Study start (actual)2020-07-26Date precision: day

Registry last updated2023-12-06

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non Small Cell Lung Cancerunresolved

Interventions

CamrelizumabDRUG

Sponsors & collaborators

Shanghai Pulmonary Hospital, Shanghai, Chinalead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04379739 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.